Spotlight Innovation Inc. announced that the United States Patent and Trademark Office (USPTO) issued to the company's subsidiary Celtic Biotech Iowa US Patent No. 9,345,751, entitled "Crotalus Durissus Terrificus Venom Administration for Cancer Treatment." The patented invention relates to compositions isolated from rattlesnake venom (Crotoxin) and methods for intravenous administration of Crotoxin to cancer patients.

Commenting on the significance of this patent issuance, Cristopher Grunewald, Spotlight Innovation's president and chief executive officer, said, "A key component of Spotlight Innovation's product development strategy is to establish a strong intellectual property portfolio to support our pipeline of therapeutic product candidates."

Spotlight Innovation Inc. identifies and acquires rights to innovative, proprietary technologies designed to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases.